Zimmer Biomet Holdings, Inc.

Zimmer Biomet Holdings, Inc.

ZBHNYSE / NASDAQHealthcareLarge cap

$101.10-$0.37 (-0.4%)

Last close · Data as of Nov 20, 2026

Market cap
$16.8B
P/E
23.8x
EV / EBITDA
10.7x
Revenue
$8.2B
Net margin
8.6%
ROCE
6.6%

+13.5% over the last year

Zimmer Biomet Holdings, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+5.3%
3M
+2.2%
6M
+18.4%
1Y
+13.5%
5Y
-19.2%

52-week range

Day change -$0.37 (-0.4%) from $101 to $101 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in ZBH, bought on each weekday since 2021.

News & filings

What Zimmer Biomet Holdings filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernReturn on equity of 5.6% against a peer median of 7.4%.

Strengths (1)

  • Operating margin of 16.5% against a peer median of 12.8%.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide.

Read moreShow less

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Sector
Healthcare
Shares outstanding
198.1M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$16.8B
P/E
23.8x
P/B
1.3x
EV / EBITDA
10.7x
EV / Sales
2.9x
P/S
2.0x
52-week high
$110.15
52-week low
$79.58

Profitability

Operating margin
16.5%
Net margin
8.6%
EBITDA margin
26.9%
ROE
5.6%
ROCE
6.6%
ROA
3.1%
Asset turnover
0.36

Growth

Revenue
$8.2B
Revenue growth, 1Y
7.2%
Revenue CAGR, 3Y
5.9%
Net profit growth, 1Y
-22.0%
Free cash flow
$1.4B

Solvency

Current ratio
1.98
Debt / Equity
0.59
Debt / Assets
0.33
CFO / Net profit
2.41
Cash / Market cap
3.5%

Where the revenue went

Of every $100 of FY2025 revenue, $9 was left as net income.

Zimmer Biomet Holdings, Inc. income statement flow, FY2025
Zimmer Biomet Holdings, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$2.5B
RevenueGross profit$5.7B
Gross profitResearch and development$458.5M
Gross profitSelling, general and administrative$3.3B
Gross profitOther operating expenses$665.9M
Gross profitOperating income$1.4B
Operating incomePretax income$830.8M
Operating incomeInterest and other expense$525.4M
Pretax incomeTax and other$125.7M
Pretax incomeNet income$705.1M

Revenue and net profit

Revenue grew 7.2% in FY2025; net profit is the dashed line.

Zimmer Biomet Holdings, Inc. revenue and net profit by fiscal year
Zimmer Biomet Holdings, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$6.9B$231.4M
FY2023$7.4B$1.0B
FY2024$7.7B$903.8M
FY2025$8.2B$705.1M

Cash flows

FY2025: $1.7B from operations, $1.4B free after investment (dashed).

Zimmer Biomet Holdings, Inc. operating and free cash flow by fiscal year
Zimmer Biomet Holdings, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$1.3B$1.1B
FY2023$1.6B$1.2B
FY2024$1.5B$1.1B
FY2025$1.7B$1.4B

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$8.2B+7.2%1Y
EBITDA
$2.2B-1.5%1Y
Net profit
$705.1M-22.0%1Y
Cash from operations
$1.7B+13.2%1Y
Free cash flow
$1.4B+24.3%1Y
Revenue CAGR, 3Y
5.9%
Net profit CAGR, 3Y
45.0%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$8.2B$2.2B$705.1M$1.4B5.6%+7.2%-22.0%

Monthly returns

Month-by-month returns of ZBH across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$23.1B
Liabilities$10.4B
Equity$12.7B
Paid-in capital$10.2B
Retained earnings$11.6B
Treasury stock$8.9B
Minority interest$8.1M

Market cap against peers

8 peers: same sector, nearest by size.

  1. Zimmer Biomet Holdings, Inc. (this company)$16.8B

Peers map

Healthcare companies placed by value, growth and quality; ZBH highlighted.

P/E against peers

ZBH trades at 23.8x earnings against a peer median of 16.5x (a 44% premium).

  1. Zimmer Biomet Holdings, Inc. (this company)23.8x

Not shown (no positive earnings and no EV / Sales): Moderna, Inc., Viatris Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Zimmer Biomet Holdings, Inc.ZBHthis companyP/E ↑ premium$16.8B23.8x1.3x5.6%10.7x
Labcorp Holdings Inc.LH$21.4B24.4x2.5x10.2%13.6x
STERIS plcSTE$20.7B26.5x2.9x10.9%14.0x
Moderna, Inc.MRNA$20.5B-7.3x2.4x-32.6%-7.5x
Incyte CorporationINCY$20.2B15.7x3.9x24.9%9.8x
Viatris Inc.VTRS$18.5B—1.3x-23.9%—
Solventum CorporationSOLV$14.3B9.2x2.8x30.8%7.2x
DaVita Inc.DVA$12.3B16.5x-18.9x-114.7%9.3x
The Cooper Companies, Inc.COO$12.1B32.3x1.5x4.6%13.9x
Peer median—16.5x2.4x7.4%9.8x

Year-to-date ROI

ZBH since 1 January, against earlier years.

Historical volatility

ZBH's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Zimmer Biomet Holdings, Inc. operating margin by fiscal year
Zimmer Biomet Holdings, Inc. operating margin by fiscal year
DateOperating margin
FY202217.2%
FY202319.6%
FY202419.9%
FY202516.5%
LineFY2025
Cost of revenueCost Of Revenue$2.5B
Gross profitGross Profit$5.7B
Operating expensesOperating Expense$4.4B
Research and developmentResearch And Development$458.5M
Selling, general and administrativeSelling General And Administration$3.3B
Other operating expensesOther Operating Expenses—
Depreciation and amortisationDepreciation And Amortization In Income Statement$665.9M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$665.9M
Amortization$665.9M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$665.9M
Total expensesTotal Expenses$6.9B
Pretax incomePretax Income$830.8M

Learn while you research

Academy chapters picked for Zimmer Biomet Holdings, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  3. 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  4. 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →